Endologix LLC announced the submission of a Premarket Approval (PMA) application requesting approval for the DETOUR System to the U.S. Food and Drug Administration (FDA). The DETOUR System, which earned FDA Breakthrough Device Designation, is a unique therapy that allows the creation of a fully percutaneous femoropopliteal bypass that is routed through the femoral vein. The DETOUR System uses the ENDOCROSSTM Device and TORUSTM Stent Graft to treat patients with moderate to severe peripheral arterial disease with long blockages of the superficial femoral artery.